Poly Medicure Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 18, 2025, 2:50 am

Competitors of Poly Medicure Ltd

All Competitor Stocks of Poly Medicure Ltd

Quarterly Result

Last Updated: August 20, 2025, 5:25 am

Below is a detailed analysis of the quarterly data for Poly Medicure Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 403.00 Cr.. The value appears to be declining and may need further review. It has decreased from 441.00 Cr. (Mar 2025) to 403.00 Cr., marking a decrease of 38.00 Cr..
• For Expenses, as of Jun 2025, the value is 297.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 321.00 Cr. (Mar 2025) to 297.00 Cr., marking a decrease of 24.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 106.00 Cr.. The value appears to be declining and may need further review. It has decreased from 119.00 Cr. (Mar 2025) to 106.00 Cr., marking a decrease of 13.00 Cr..
• For OPM %, as of Jun 2025, the value is 26.00%. The value appears to be declining and may need further review. It has decreased from 27.00% (Mar 2025) to 26.00%, marking a decrease of 1.00%.
• For Other Income, as of Jun 2025, the value is 43.00 Cr.. The value appears strong and on an upward trend. It has increased from 27.00 Cr. (Mar 2025) to 43.00 Cr., marking an increase of 16.00 Cr..
• For Interest, as of Jun 2025, the value is 3.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.00 Cr. (Mar 2025) to 3.00 Cr., marking an increase of 1.00 Cr..
• For Depreciation, as of Jun 2025, the value is 23.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 21.00 Cr. (Mar 2025) to 23.00 Cr., marking an increase of 2.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 123.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 123.00 Cr..
• For Tax %, as of Jun 2025, the value is 24.00%. The value appears to be improving (decreasing) as expected. It has decreased from 25.00% (Mar 2025) to 24.00%, marking a decrease of 1.00%.
• For Net Profit, as of Jun 2025, the value is 93.00 Cr.. The value appears strong and on an upward trend. It has increased from 92.00 Cr. (Mar 2025) to 93.00 Cr., marking an increase of 1.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 9.19. The value appears strong and on an upward trend. It has increased from 9.06 (Mar 2025) to 9.19, marking an increase of 0.13.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: November 15, 2025, 4:41 am

Growth

Last Updated: September 5, 2025, 12:20 pm

Balance Sheet

Last Updated: November 9, 2025, 2:43 pm

Below is a detailed analysis of the balance sheet data for Poly Medicure Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

• For Equity Capital, as of Sep 2025, the value is 51.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 51.00 Cr..
• For Reserves, as of Sep 2025, the value is 2,868.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,715.00 Cr. (Mar 2025) to 2,868.00 Cr., marking an increase of 153.00 Cr..
• For Borrowings, as of Sep 2025, the value is 240.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 180.00 Cr. (Mar 2025) to 240.00 Cr., marking an increase of 60.00 Cr..
• For Other Liabilities, as of Sep 2025, the value is 429.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 246.00 Cr. (Mar 2025) to 429.00 Cr., marking an increase of 183.00 Cr..
• For Total Liabilities, as of Sep 2025, the value is 3,587.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,192.00 Cr. (Mar 2025) to 3,587.00 Cr., marking an increase of 395.00 Cr..
• For Fixed Assets, as of Sep 2025, the value is 1,439.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,084.00 Cr. (Mar 2025) to 1,439.00 Cr., marking an increase of 355.00 Cr..
• For CWIP, as of Sep 2025, the value is 83.00 Cr.. The value appears to be declining and may need further review. It has decreased from 101.00 Cr. (Mar 2025) to 83.00 Cr., marking a decrease of 18.00 Cr..
• For Investments, as of Sep 2025, the value is 930.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,077.00 Cr. (Mar 2025) to 930.00 Cr., marking a decrease of 147.00 Cr..
• For Other Assets, as of Sep 2025, the value is 1,135.00 Cr.. The value appears strong and on an upward trend. It has increased from 930.00 Cr. (Mar 2025) to 1,135.00 Cr., marking an increase of 205.00 Cr..
• For Total Assets, as of Sep 2025, the value is 3,587.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,192.00 Cr. (Mar 2025) to 3,587.00 Cr., marking an increase of 395.00 Cr..

Notably, the Reserves (2,868.00 Cr.) exceed the Borrowings (240.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Poly Medicure Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 34.13. This value is within the healthy range. It has increased from 26.92 (Mar 24) to 34.13, marking an increase of 7.21.
• For Diluted EPS (Rs.), as of Mar 25, the value is 34.11. This value is within the healthy range. It has increased from 26.90 (Mar 24) to 34.11, marking an increase of 7.21.
• For Cash EPS (Rs.), as of Mar 25, the value is 41.06. This value is within the healthy range. It has increased from 33.31 (Mar 24) to 41.06, marking an increase of 7.75.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 272.95. It has increased from 153.18 (Mar 24) to 272.95, marking an increase of 119.77.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 272.95. It has increased from 153.18 (Mar 24) to 272.95, marking an increase of 119.77.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 164.80. It has increased from 143.35 (Mar 24) to 164.80, marking an increase of 21.45.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 53.49. This value is within the healthy range. It has increased from 43.45 (Mar 24) to 53.49, marking an increase of 10.04.
• For PBIT / Share (Rs.), as of Mar 25, the value is 45.33. This value is within the healthy range. It has increased from 36.79 (Mar 24) to 45.33, marking an increase of 8.54.
• For PBT / Share (Rs.), as of Mar 25, the value is 44.15. This value is within the healthy range. It has increased from 35.61 (Mar 24) to 44.15, marking an increase of 8.54.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 32.90. This value is within the healthy range. It has increased from 26.65 (Mar 24) to 32.90, marking an increase of 6.25.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 33.41. This value is within the healthy range. It has increased from 26.91 (Mar 24) to 33.41, marking an increase of 6.50.
• For PBDIT Margin (%), as of Mar 25, the value is 32.45. This value is within the healthy range. It has increased from 30.30 (Mar 24) to 32.45, marking an increase of 2.15.
• For PBIT Margin (%), as of Mar 25, the value is 27.50. This value exceeds the healthy maximum of 20. It has increased from 25.66 (Mar 24) to 27.50, marking an increase of 1.84.
• For PBT Margin (%), as of Mar 25, the value is 26.78. This value is within the healthy range. It has increased from 24.83 (Mar 24) to 26.78, marking an increase of 1.95.
• For Net Profit Margin (%), as of Mar 25, the value is 19.96. This value exceeds the healthy maximum of 10. It has increased from 18.58 (Mar 24) to 19.96, marking an increase of 1.38.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 20.27. This value exceeds the healthy maximum of 20. It has increased from 18.77 (Mar 24) to 20.27, marking an increase of 1.50.
• For Return on Networth / Equity (%), as of Mar 25, the value is 12.24. This value is below the healthy minimum of 15. It has decreased from 17.56 (Mar 24) to 12.24, marking a decrease of 5.32.
• For Return on Capital Employeed (%), as of Mar 25, the value is 16.27. This value is within the healthy range. It has decreased from 23.42 (Mar 24) to 16.27, marking a decrease of 7.15.
• For Return On Assets (%), as of Mar 25, the value is 10.60. This value is within the healthy range. It has decreased from 13.89 (Mar 24) to 10.60, marking a decrease of 3.29.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.06. This value is within the healthy range. It has decreased from 0.11 (Mar 24) to 0.06, marking a decrease of 0.05.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.66. It has decreased from 0.80 (Mar 24) to 0.66, marking a decrease of 0.14.
• For Current Ratio (X), as of Mar 25, the value is 5.18. This value exceeds the healthy maximum of 3. It has increased from 2.40 (Mar 24) to 5.18, marking an increase of 2.78.
• For Quick Ratio (X), as of Mar 25, the value is 4.41. This value exceeds the healthy maximum of 2. It has increased from 1.77 (Mar 24) to 4.41, marking an increase of 2.64.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.26. This value is below the healthy minimum of 4. It has increased from 2.16 (Mar 24) to 2.26, marking an increase of 0.10.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 11.14 (Mar 24) to 0.00, marking a decrease of 11.14.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 8.93 (Mar 24) to 0.00, marking a decrease of 8.93.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 88.86 (Mar 24) to 0.00, marking a decrease of 88.86.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 91.07 (Mar 24) to 0.00, marking a decrease of 91.07.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 45.18. This value is within the healthy range. It has increased from 36.90 (Mar 24) to 45.18, marking an increase of 8.28.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 28.79. This value is within the healthy range. It has increased from 23.63 (Mar 24) to 28.79, marking an increase of 5.16.
• For Enterprise Value (Cr.), as of Mar 25, the value is 22,744.56. It has increased from 15,271.32 (Mar 24) to 22,744.56, marking an increase of 7,473.24.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 13.62. This value exceeds the healthy maximum of 3. It has increased from 11.10 (Mar 24) to 13.62, marking an increase of 2.52.
• For EV / EBITDA (X), as of Mar 25, the value is 41.97. This value exceeds the healthy maximum of 15. It has increased from 36.62 (Mar 24) to 41.97, marking an increase of 5.35.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 13.61. This value exceeds the healthy maximum of 3. It has increased from 11.08 (Mar 24) to 13.61, marking an increase of 2.53.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 88.85 (Mar 24) to 0.00, marking a decrease of 88.85.
• For Price / BV (X), as of Mar 25, the value is 8.21. This value exceeds the healthy maximum of 3. It has decreased from 10.37 (Mar 24) to 8.21, marking a decrease of 2.16.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 13.61. This value exceeds the healthy maximum of 3. It has increased from 11.08 (Mar 24) to 13.61, marking an increase of 2.53.
• For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness